-
-
-
-
-
-
-
Coherus BioSciences (CHRS) and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
-
-
-
-
-
-
-
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
-
-
-
-
-
-
-
Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
-
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

